4.5 Article

Impact of individual platelet lysates on isolation and growth of human mesenchymal stromal cells

期刊

CYTOTHERAPY
卷 12, 期 7, 页码 888-898

出版社

ELSEVIER SCI LTD
DOI: 10.3109/14653249.2010.501788

关键词

colony-forming units; cytokine profile; fetal calf serum; long-term culture; mesenchymal stromal cells; platelet lysate

资金

  1. German Ministry of Education and Research (BMBF)
  2. German Research Foundation DFG [HO 914/7-1]
  3. Heidelberg Academy of Sciences (WIN-Kolleg)
  4. Excellence initiative of the German federal and state governments
  5. Stem Cell Network North Rhine Westphalia

向作者/读者索取更多资源

Background aims. Culture medium for mesenchymal stromal cells (MSC) is frequently supplemented with fetal calf serum (FCS). FCS can induce xenogeneic immune reactions, transmit bovine pathogens and has a high lot-to-lot variability that hampers reproducibility of results. Several studies have demonstrated that pooled human platelet lysate (HPL) provides an attractive alternative for FCS. However, little is known about the variation between different platelet lysates. Methods. We compared activities of individual HPL on initial fibroblastoid colony-forming units (CFU-F), proliferation, in vitro differentiation and long-term culture. These data were correlated with chemokine profiles of HPL. Results. Isolation of MSC with either HPL or FCS resulted in similar CFU-F frequency, colony morphology, immunophenotype and adipogenic differentiation potential. Osteogenic differentiation was even more pronounced in HPL than FCS. There were significant differences in MSC proliferation with different HPL, but it was always higher in comparison with FCS. Cell growth correlated with the concentration of platelet-derived growth factor (PDGF) and there was a moderate association with platelet counts. All HPL facilitated expansion for more than 20 population doublings. Conclusions. Taken together, reliable long-term expansion was possible with all HPL, although there was some variation in platelet lysates of individual units. Therefore the use of donor recipient-matched or autologous HPL is feasible for therapeutic MSC products.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据